These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 26609872)

  • 21. [New antiarrhythmic drugs for therapy of atrial fibrillation: I. Ion channel blockers].
    Ravens U; Wettwer E; Schotten U; Wessel R; Dobrev D
    Herzschrittmacherther Elektrophysiol; 2006 Jun; 17(2):64-72. PubMed ID: 16786464
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early management of atrial fibrillation to prevent cardiovascular complications.
    Nattel S; Guasch E; Savelieva I; Cosio FG; Valverde I; Halperin JL; Conroy JM; Al-Khatib SM; Hess PL; Kirchhof P; De Bono J; Lip GY; Banerjee A; Ruskin J; Blendea D; Camm AJ
    Eur Heart J; 2014 Jun; 35(22):1448-56. PubMed ID: 24536084
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Age as a Critical Determinant of Atrial Fibrillation: A Two-sided Relationship.
    Laredo M; Waldmann V; Khairy P; Nattel S
    Can J Cardiol; 2018 Nov; 34(11):1396-1406. PubMed ID: 30404745
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cellular and molecular correlates of ectopic activity in patients with atrial fibrillation.
    Voigt N; Dobrev D
    Europace; 2012 Nov; 14 Suppl 5():v97-v105. PubMed ID: 23104921
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanisms and Drug Development in Atrial Fibrillation.
    Calvo D; Filgueiras-Rama D; Jalife J
    Pharmacol Rev; 2018 Jul; 70(3):505-525. PubMed ID: 29921647
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted pharmacological reversal of electrical remodeling after cardioversion--rationale and design of the Flecainide Short-Long (Flec-SL) trial.
    Kirchhof P; Fetsch T; Hanrath P; Meinertz T; Steinbeck G; Lehmacher W; Breithardt G
    Am Heart J; 2005 Nov; 150(5):899. PubMed ID: 16290956
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pathophysiology and disease progression of atrial fibrillation: importance of achieving and maintaining sinus rhythm.
    Cohen M; Naccarelli GV
    J Cardiovasc Electrophysiol; 2008 Aug; 19(8):885-90. PubMed ID: 18373600
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New drugs for atrial fibrillation.
    Hammwöhner M; Smid J; Lendeckel U; Goette A
    J Interv Card Electrophysiol; 2008 Oct; 23(1):15-21. PubMed ID: 18535890
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiarrhythmic drug therapy for atrial fibrillation.
    Sardar MR; Saeed W; Kowey PR
    Cardiol Clin; 2014 Nov; 32(4):533-49. PubMed ID: 25443235
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Atrial fibrillation in congestive heart failure.
    Seiler J; Stevenson WG
    Cardiol Rev; 2010; 18(1):38-50. PubMed ID: 20010337
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advances in the treatment of atrial fibrillation.
    Miranda RI; Simpson CS; Michael KA; Abdollah H; Baranchuk AM; Redfearn DP
    Minerva Cardioangiol; 2010 Dec; 58(6):637-48. PubMed ID: 21135805
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Atrial fibrillation and heart failure: natural history and pharmacological treatment.
    Savelieva I; John Camm A
    Europace; 2004 Sep; 5 Suppl 1():S5-19. PubMed ID: 15450275
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improving outcomes in patients with atrial fibrillation: rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial.
    Kirchhof P; Breithardt G; Camm AJ; Crijns HJ; Kuck KH; Vardas P; Wegscheider K
    Am Heart J; 2013 Sep; 166(3):442-8. PubMed ID: 24016492
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Atrial fibrillation pathophysiology: implications for management.
    Iwasaki YK; Nishida K; Kato T; Nattel S
    Circulation; 2011 Nov; 124(20):2264-74. PubMed ID: 22083148
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of atrial fibrillation.
    Bajpai A; Savelieva I; Camm AJ
    Br Med Bull; 2008; 88(1):75-94. PubMed ID: 19059992
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rhythm control versus rate control in patients with persistent atrial fibrillation. Results of the HOT CAFE Polish Study.
    Opolski G; Torbicki A; Kosior D; Szulc M; Zawadzka M; Pierścińska M; Kołodziej P; Stopiński M; Wozakowska-Kapłon B; Achremczyk P; Rabczenko D
    Kardiol Pol; 2003 Jul; 59(7):1-16; discussion 15-16. PubMed ID: 14560344
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Atrial fibrillation: basic mechanisms, remodeling and triggers.
    Shiroshita-Takeshita A; Brundel BJ; Nattel S
    J Interv Card Electrophysiol; 2005 Sep; 13(3):181-93. PubMed ID: 16177845
    [No Abstract]   [Full Text] [Related]  

  • 38. Type 2 diabetes mellitus and atrial fibrillation: From mechanisms to clinical practice.
    Tadic M; Cuspidi C
    Arch Cardiovasc Dis; 2015 Apr; 108(4):269-76. PubMed ID: 25858534
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiarrhythmic therapy in atrial fibrillation.
    Ravens U
    Pharmacol Ther; 2010 Oct; 128(1):129-45. PubMed ID: 20624425
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms.
    Andrade J; Khairy P; Dobrev D; Nattel S
    Circ Res; 2014 Apr; 114(9):1453-68. PubMed ID: 24763464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.